These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
209 related articles for article (PubMed ID: 35580282)
1. Monthly injectable cabotegravir/rilpivirine to manage HIV infection in adults. Blackwell CW; López Castillo H J Am Assoc Nurse Pract; 2022 Jul; 34(7):918-923. PubMed ID: 35580282 [TBL] [Abstract][Full Text] [Related]
2. Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial. Margolis DA; Gonzalez-Garcia J; Stellbrink HJ; Eron JJ; Yazdanpanah Y; Podzamczer D; Lutz T; Angel JB; Richmond GJ; Clotet B; Gutierrez F; Sloan L; Clair MS; Murray M; Ford SL; Mrus J; Patel P; Crauwels H; Griffith SK; Sutton KC; Dorey D; Smith KY; Williams PE; Spreen WR Lancet; 2017 Sep; 390(10101):1499-1510. PubMed ID: 28750935 [TBL] [Abstract][Full Text] [Related]
3. Long-acting Injectable Cabotegravir/Rilpivirine Effective in a Small Patient Cohort With Virologic Failure on Oral Antiretroviral Therapy. Brock JB; Herrington P; Hickman M; Hickman A Clin Infect Dis; 2024 Jan; 78(1):122-124. PubMed ID: 37740255 [TBL] [Abstract][Full Text] [Related]
4. Cabotegravir/Rilpivirine: the last FDA-approved drug to treat HIV. Taki E; Soleimani F; Asadi A; Ghahramanpour H; Namvar A; Heidary M Expert Rev Anti Infect Ther; 2022 Aug; 20(8):1135-1147. PubMed ID: 35596583 [TBL] [Abstract][Full Text] [Related]
5. The potential role of long-acting injectable cabotegravir-rilpivirine in the treatment of HIV in sub-Saharan Africa: a modelling analysis. Phillips AN; Bansi-Matharu L; Cambiano V; Ehrenkranz P; Serenata C; Venter F; Pett S; Flexner C; Jahn A; Revill P; Garnett GP Lancet Glob Health; 2021 May; 9(5):e620-e627. PubMed ID: 33770513 [TBL] [Abstract][Full Text] [Related]
6. Cabotegravir: a novel HIV integrase inhibitor combined with rilpivirine as the first long-acting injectable program for the treatment of HIV infection. Zeuli JD; Rivera CG; Smith BL; Otto A; Temesgen Z Drugs Today (Barc); 2022 Dec; 58(12):555-576. PubMed ID: 36651065 [TBL] [Abstract][Full Text] [Related]
7. Safety and pharmacokinetics of oral and long-acting injectable cabotegravir or long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study. Gaur AH; Capparelli EV; Calabrese K; Baltrusaitis K; Marzinke MA; McCoig C; Van Solingen-Ristea RM; Mathiba SR; Adeyeye A; Moye JH; Heckman B; Lowenthal ED; Ward S; Milligan R; Samson P; Best BM; Harrington CM; Ford SL; Huang J; Crauwels H; Vandermeulen K; Agwu AL; Smith-Anderson C; Camacho-Gonzalez A; Ounchanum P; Kneebone JL; Townley E; Bolton Moore C; ; Lancet HIV; 2024 Apr; 11(4):e211-e221. PubMed ID: 38538160 [TBL] [Abstract][Full Text] [Related]
8. Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study. Orkin C; Bernal Morell E; Tan DHS; Katner H; Stellbrink HJ; Belonosova E; DeMoor R; Griffith S; Thiagarajah S; Van Solingen-Ristea R; Ford SL; Crauwels H; Patel P; Cutrell A; Smith KY; Vandermeulen K; Birmingham E; St Clair M; Spreen WR; D'Amico R Lancet HIV; 2021 Nov; 8(11):e668-e678. PubMed ID: 34656207 [TBL] [Abstract][Full Text] [Related]
9. Cabotegravir Plus Rilpivirine: First Approval. Markham A Drugs; 2020 Jun; 80(9):915-922. PubMed ID: 32495274 [TBL] [Abstract][Full Text] [Related]
10. An evaluation of long-acting cabotegravir + rilpivirine for the treatment of virologically suppressed adults living with HIV. Qazzaz H; Parganas C; Cory TJ Expert Opin Pharmacother; 2022 Sep; 23(13):1485-1495. PubMed ID: 36124818 [TBL] [Abstract][Full Text] [Related]
11. Acceptability and tolerability of long-acting injectable cabotegravir or rilpivirine in the first cohort of virologically suppressed adolescents living with HIV (IMPAACT 2017/MOCHA): a secondary analysis of a phase 1/2, multicentre, open-label, non-comparative dose-finding study. Lowenthal ED; Chapman J; Ohrenschall R; Calabrese K; Baltrusaitis K; Heckman B; Yin DE; Agwu AL; Harrington C; Van Solingen-Ristea RM; McCoig CC; Adeyeye A; Kneebone J; Chounta V; Smith-Anderson C; Camacho-Gonzalez A; D'Angelo J; Bearden A; Crauwels H; Huang J; Buisson S; Milligan R; Ward S; Bolton-Moore C; Gaur AH; ; Lancet HIV; 2024 Apr; 11(4):e222-e232. PubMed ID: 38538161 [TBL] [Abstract][Full Text] [Related]
12. Impact of Integrase Sequences from HIV-1 Subtypes A6/A1 on the Jeffrey JL; St Clair M; Wang P; Wang C; Li Z; Beloor J; Talarico C; Fridell R; Krystal M; White CT; Griffith S; D'Amico R; Smith K; Van Eygen V; Vingerhoets J; Vandermeulen K; Spreen W; van Lunzen J Antimicrob Agents Chemother; 2022 Mar; 66(3):e0170221. PubMed ID: 34978890 [TBL] [Abstract][Full Text] [Related]
13. Perspectives of people living with HIV-1 on implementation of long-acting cabotegravir plus rilpivirine in US healthcare settings: results from the CUSTOMIZE hybrid III implementation-effectiveness study. Garris CP; Czarnogorski M; Dalessandro M; D'Amico R; Nwafor T; Williams W; Merrill D; Wang Y; Stassek L; Wohlfeiler MB; Sinclair GI; Mena LA; Thedinger B; Flamm JA; Benson P; Spreen WR J Int AIDS Soc; 2022 Sep; 25(9):e26006. PubMed ID: 36097674 [TBL] [Abstract][Full Text] [Related]
14. Perspectives of healthcare providers on implementation of long-acting cabotegravir plus rilpivirine in US healthcare settings from a Hybrid III Implementation-effectiveness study (CUSTOMIZE). Czarnogorski M; Garris CP; Dalessandro M; D'Amico R; Nwafor T; Williams W; Merrill D; Wang Y; Stassek L; Wohlfeiler MB; Sinclair GI; Mena LA; Thedinger B; Flamm JA; Benson P; Spreen WR J Int AIDS Soc; 2022 Sep; 25(9):e26003. PubMed ID: 36094142 [TBL] [Abstract][Full Text] [Related]
15. Contribution of cabotegravir + rilpivirine long-acting for the treatment of HIV-1 infection. Calleja-Hernández MÁ; Martinez-Sesmero JM; Vallejo-Aparicio LA; Hernández-Novoa B; Badia X Farm Hosp; 2022 Jul; 46(4):208-214. PubMed ID: 36183218 [TBL] [Abstract][Full Text] [Related]
16. Brief Report: Impact of COVID-19 on Cabotegravir Plus Rilpivirine Long-Acting Dosing Across 6 Ongoing Global Phase IIb and III Clinical Trials. Czarnogorski M; Benn P; McCoig C; Nwafor T; Griffith S; Sutton K; Harrington C; Saggu P; Yague I; Williams W; Español CM; Goodchild J; Fricker J; Patel P; D'Amico R J Acquir Immune Defic Syndr; 2022 Oct; 91(2):157-161. PubMed ID: 36094481 [TBL] [Abstract][Full Text] [Related]
17. Are we ready for long-acting? A feasibility evaluation of long-acting cabotegravir-rilpivirine in clinical practice. Borghetti A; Farinacci D; Ciccullo A; Dusina A; Moschese D; Iannone V; D'Angelillo A; Lombardi F; Donne VD; Massaroni V; Visconti E; Tamburrini E; Di Giambenedetto S J Med Virol; 2022 Oct; 94(10):4970-4974. PubMed ID: 35638227 [TBL] [Abstract][Full Text] [Related]
19. First Extended-Release Injectable Drug Therapy for HIV. Aschenbrenner DS Am J Nurs; 2021 May; 121(5):24-25. PubMed ID: 33872258 [TBL] [Abstract][Full Text] [Related]
20. Favorable Virological Outcome, Characteristics of Injection Site Reactions, Decrease in Renal Function Biomarkers in Asian People with HIV Receiving Long-Acting Cabotegravir Plus Rilpivirine. Adachi E; Saito M; Otani A; Koga M; Yotsuyanagi H AIDS Res Hum Retroviruses; 2024 Apr; 40(4):216-222. PubMed ID: 38164081 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]